Understanding Multiple Sclerosis Pathophysiology and Current Disease-Modifying Therapies: A Review of Unaddressed Aspects
- PMID: 39614433
- DOI: 10.31083/j.fbl2911386
Understanding Multiple Sclerosis Pathophysiology and Current Disease-Modifying Therapies: A Review of Unaddressed Aspects
Abstract
Multiple sclerosis (MS) is a complex autoimmune disorder of the central nervous system (CNS) with an unknown etiology and pathophysiology that is not completely understood. Although great strides have been made in developing disease-modifying therapies (DMTs) that have significantly improved the quality of life for MS patients, these treatments do not entirely prevent disease progression or relapse. Identifying the unaddressed pathophysiological aspects of MS and developing targeted therapies to fill in these gaps are essential in providing long-term relief for patients. Recent research has uncovered some aspects of MS that remain outside the scope of available DMTs, and as such, yield only limited benefits. Despite most MS pathophysiology being targeted by DMTs, many patients still experience disease progression or relapse, indicating that a more detailed understanding is necessary. Thus, this literature review seeks to explore the known aspects of MS pathophysiology, identify the gaps in present DMTs, and explain why current treatments cannot entirely arrest MS progression.
Keywords: MS pathogenesis; MS therapies; experimental autoimmune encephalomyelitis; immune system; multiple sclerosis (MS); neurodegenerative disorder.
© 2024 The Author(s). Published by IMR Press.
Similar articles
-
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Mayo Clin Proc. 2014. PMID: 24485135 Review.
-
Diagnosis and Treatment of Multiple Sclerosis: A Review.JAMA. 2021 Feb 23;325(8):765-779. doi: 10.1001/jama.2020.26858. JAMA. 2021. PMID: 33620411 Review.
-
Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.Adv Ther. 2020 Jul;37(7):3163-3177. doi: 10.1007/s12325-020-01367-1. Epub 2020 May 20. Adv Ther. 2020. PMID: 32436028 Free PMC article.
-
Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation.Autoimmun Rev. 2024 Feb;23(2):103480. doi: 10.1016/j.autrev.2023.103480. Epub 2023 Nov 25. Autoimmun Rev. 2024. PMID: 38008300 Review.
-
Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.Curr Top Med Chem. 2020;20(26):2391-2403. doi: 10.2174/1568026620666200924114827. Curr Top Med Chem. 2020. PMID: 32972341 Review.
Cited by
-
Acute Myocardial Infarction and Diffuse Coronary Artery Disease in a Patient with Multiple Sclerosis: A Case Report and Literature Review.J Clin Med. 2025 Jun 17;14(12):4304. doi: 10.3390/jcm14124304. J Clin Med. 2025. PMID: 40566048 Free PMC article. Review.
-
TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases.Int J Mol Sci. 2025 Aug 14;26(16):7839. doi: 10.3390/ijms26167839. Int J Mol Sci. 2025. PMID: 40869160 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical